Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

42.23 +2.12 (+5.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
Via FinancialNewsMedia
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
News headline image
Moderna Announces Health Canada Approves its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
Via FinancialNewsMedia
News headline image
Moderna Highlights New Clinical Data on its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
From Moderna, Inc.
Via Business Wire
News headline image
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
From Moderna, Inc.
Via Business Wire
News headline image
Moderna to Present at Upcoming Investor Conferences in September 2021
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna to Host Virtual R&D Day on Thursday, September 9, 2021
From Moderna, Inc.
Via Business Wire
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
Via FinancialNewsMedia
News headline image
Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months
From Moderna, Inc.
Via Business Wire
News headline image
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada
From ModernaTX, Inc.
Via Business Wire
News headline image
Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Named Fast Company’s 2021 Best Workplace for Innovators
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic
From Moderna, Inc.
Via Business Wire
News headline image
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Announces Establishment of New Charitable Foundation
From Moderna, Inc.
Via Business Wire
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
Via FinancialNewsMedia
News headline image
Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023
From Moderna, Inc.
Via Business Wire
News headline image
Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022
From Moderna, Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.